公开(公告)号：US09458447B2

公开(公告)日：2016-10-04

申请号：US14131019

申请日：2012-08-09

Applicant: Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Yusuke Nakamura

IPC: C07K7/00 ,  A61K38/10 ,  C12N9/00 ,  A61K39/00 ,  C07K14/47 ,  C12N9/14 ,  G01N33/50 ,  C12N5/0784 ,  C12N5/10 ,  G01N33/574 ,  A61K38/00

CPC classification number: C12N9/93 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4738 ,  C12N5/0639 ,  C12N5/10 ,  C12N9/14 ,  C12N2502/1114 ,  C12Y306/04004 ,  G01N33/505 ,  G01N33/57407 ,  G01N2440/14

Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.

Abstract translation: 如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性 原始序列。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。 本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠 癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。

公开(公告)号：US09169927B2

公开(公告)日：2015-10-27

申请号：US13020847

申请日：2011-02-04

Applicant: Yusuke Nakamura ,  Hiroyuki Sato

Inventor： Yusuke Nakamura ,  Hiroyuki Sato

IPC: F16H59/68 ,  F16H61/662 ,  F16H59/20 ,  F16H61/02

CPC classification number: F16H61/66259 ,  F16H59/20 ,  F16H2061/0227

Abstract: There is provided a shift control apparatus of an automatic transmission in a vehicle including a constant speed traveling apparatus, which has a detecting device detecting a surrounding situation of the vehicle and operates according to the detected situation, and an automatic transmission capable of steplessly changing a transmission ratio, the shift control apparatus controlling the automatic transmission according to a shift map for changing the transmission ratio according to a traveling state. The shift control apparatus includes a plurality of shift maps, and a switching and selecting unit selecting and switching to one of the shift maps based on a shift-down request signal or a requested acceleration, which is outputted by a constant speed traveling control device of the constant speed traveling apparatus, according to the situation detected by the detecting device.

Abstract translation: 本发明提供一种车辆中的自动变速器的变速控制装置，其包括：恒速行驶装置，其具有检测车辆的周围状况的检测装置，并根据检测到的情况进行动作;以及自动变速器，其能够无级变更 传动比，变速控制装置根据行驶状态根据用于改变传动比的换档图来控制自动变速器。 变速控制装置包括多个位移图，以及切换选择单元，基于由减速请求信号或所请求的加速度来选择和切换到其中一个换档图，所述减速请求信号或所请求的加速度由恒速行驶控制装置输出 恒速行驶装置，根据检测装置检测到的情况。

公开(公告)号：US09056890B2

公开(公告)日：2015-06-16

申请号：US13880442

申请日：2011-10-20

Applicant: Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC: A61K38/00 ,  C07K7/06 ,  C07K14/47 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/47

Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.

Abstract translation: 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。

公开(公告)号：US08975086B2

公开(公告)日：2015-03-10

申请号：US13061064

申请日：2009-08-21

Applicant: Yusuke Nakamura ,  Toyomasa Katagiri ,  Akira Togashi

Inventor： Yusuke Nakamura ,  Toyomasa Katagiri ,  Akira Togashi

IPC: G01N33/53 ,  A61K38/00 ,  C07K7/00 ,  C07K14/00 ,  C07K14/82 ,  C12N15/113 ,  G01N33/50 ,  A61K48/00

CPC classification number: C07K14/82 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/10 ,  C12N15/113 ,  C12N2310/14 ,  G01N33/5011

Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides composed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.

Abstract translation: 本发明提供使用由包含DEPDC1的多肽片段的氨基酸序列组成的多肽来治疗癌症的治疗剂和方法。 本发明的多肽可以通过用转染试剂例如聚精氨酸修饰多肽而被引入到癌细胞中。 此外，本发明提供筛选用于抑制DEPDC1 / ZN-F224复合物形成或治疗癌症的治疗剂或化合物的方法。 本发明还提供靶向ZNF224基因的siRNA，其被认为可用于治疗膀胱癌。

公开(公告)号：US08755996B2

公开(公告)日：2014-06-17

申请号：US12127618

申请日：2008-05-27

Applicant: Mitsuharu Kanaboshi ,  Yukihiro Fujiwara ,  Yasushi Shoda ,  Yusuke Nakamura

Inventor： Mitsuharu Kanaboshi ,  Yukihiro Fujiwara ,  Yasushi Shoda ,  Yusuke Nakamura

IPC: G06F17/10

CPC classification number: B62D15/0265 ,  B60T2201/022 ,  B60W2420/52 ,  B60W2510/20 ,  B60W2510/205 ,  B60W2520/125 ,  B60W2520/14 ,  B60W2540/12 ,  B60W2550/306 ,  B60W2550/308 ,  B60W2710/207

Abstract: There is provided a system for immediately reflecting an intention of a driver wanting to avoid an obstacle to assistance to an avoidance operation. A vehicular operation assisting system for assisting the avoidance operation made by the driver of a vehicle in avoiding the obstacle includes an avoidance required distance calculating section for periodically calculating an avoidance required distance that is a distance required to avoid the obstacle when the obstacle is detected ahead of the vehicle, an avoidance operation determining section for periodically determining the avoidance operation with respect to the obstacle on the basis of steering maneuvers of the driver and an avoidance operation assisting degree calculating section for periodically calculating an avoidance operation assisting degree per based on the avoidance required distance calculated by the avoidance required distance calculating section and the judgment result of the avoidance operation determining section.

Abstract translation: 提供了一种系统，用于立即反映想要避免对避免操作的帮助的障碍的驾驶员的意图。 用于辅助车辆驾驶员避开障碍物的回避操作的车辆操作辅助系统包括避开需求距离计算部分，用于周期性地计算避免所需距离，该距离是当前面检测到障碍物时避开障碍物所需的距离 所述回避运算判定部根据所述驾驶员的转向动作来周期性地确定相对于所述障碍物的回避动作;以及回避运算辅助度计算部，其基于所述回避周期性地计算回避运算辅助度 由避免需要距离计算部分计算的所需距离和回避操作确定部分的判断结果。

公开(公告)号：US08709731B2

公开(公告)日：2014-04-29

申请号：US12674660

申请日：2008-08-21

Applicant: Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

Inventor： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

IPC: G01N33/53

CPC classification number: C07K16/32 ,  A61K2039/505 ,  C07K16/3046 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2800/50

Abstract: Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.

Abstract translation: 本文描述了能够治疗或预防与DKK1的过表达和/或上调相关的癌症的抗体和抗体片段。 还公开了使用抗体治疗或预防癌症的方法以及用于诊断癌症的方法和试剂盒。 本文描述的产品和方法在各种癌症如胰腺癌，胃癌，肝癌，前列腺癌，乳腺癌，子宫颈癌，胆管癌，肺癌和食管癌的情况下发现有用。

公开(公告)号：US08697631B2

公开(公告)日：2014-04-15

申请号：US13515656

申请日：2010-12-13

Applicant: Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC: C07K7/06 ,  A61K38/08 ,  G01N33/53

CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  C07K14/705

Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.

Abstract translation: 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

公开(公告)号：US08685641B2

公开(公告)日：2014-04-01

申请号：US13536327

申请日：2012-06-28

Applicant: Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

Inventor： Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

IPC: C12Q1/00

CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2500/00

Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.

Abstract translation: 本文描述了膀胱癌（BLC）检测和诊断的客观方法。 在一个实施方案中，诊断方法涉及确定鉴别BLC细胞和正常细胞的BLC相关基因的表达水平。 本发明还提供了使用具有淋巴结转移的膀胱癌细胞中具有独特改变的表达模式的BLC相关基因来预测和预防膀胱癌转移的手段。 本发明提供筛选可用于治疗膀胱癌的治疗剂的方法，治疗膀胱癌的方法和接种疫苗接种膀胱癌的方法。 具体地说，本申请提供了新的人基因C2093，B5860Ns和C6055s，其表达在膀胱癌中显着升高。 由该基因编码的基因和多肽可用于例如膀胱癌的诊断，作为用于开发针对该疾病的药物的靶分子，以及用于减轻膀胱癌的细胞生长。

公开(公告)号：US08649248B2

公开(公告)日：2014-02-11

申请号：US13479734

申请日：2012-05-24

Applicant: Koichiro Nishimura ,  Yusuke Nakamura

Inventor： Koichiro Nishimura ,  Yusuke Nakamura

IPC: G11B5/09

CPC classification number: G11B20/10009 ,  G11B7/00456 ,  G11B7/1267 ,  G11B20/10046 ,  G11B20/10055 ,  G11B20/10194 ,  G11B20/10212 ,  G11B20/10222 ,  G11B20/10481

Abstract: When a phase shift is to be evaluated, based on a difference between an output from a waveform equalization circuit to equalize an input reproduced signal to a predetermined target equalization characteristic and the target equalization characteristic, the phase shift of the reproduced signal relative to a channel clock, a group delay characteristic with respect to the frequency of the waveform equalization circuit is fixed. Hence, an equalized waveform as an output from the waveform equalization circuit can preserve phase shift information of the inputted reproduced signal to correctly detect the phase shift of the reproduced waveform using the equalized waveform. It is hence possible to realize, with high precision, optimal value learning of various parameters for the recording, reproduction, and servo by use of the phase shift as an index.

Abstract translation: 当要评估相移时，基于来自波形均衡电路的输出之间的差以将输入再现信号均衡到预定的目标均衡特性和目标均衡特性，再现信号相对于通道的相移 时钟，相对于波形均衡电路的频率的组延迟特性是固定的。 因此，作为来自波形均衡电路的输出的均衡波形可以保存输入的再现信号的相移信息，以使用均衡波形来正确地检测再现波形的相移。 因此，通过使用相移作为指标，可以高精度地实现用于记录，再现和伺服的各种参数的最佳值学习。

公开(公告)号：US20140023671A1

公开(公告)日：2014-01-23

申请号：US13990766

申请日：2011-11-25

Applicant: Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

IPC: A61K39/00 ,  C07K7/06

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  C07K14/705 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/1114 ,  C12N2502/1121 ,  G01N33/57407

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

Abstract translation: 本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。